Notice2025-12455
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 3, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 126 (Thursday, July 3, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 126 (Thursday, July 3, 2025)]
[Notices]
[Page 29573]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-12455]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Brian Bailey at 240-669-5128, or
<a href="/cdn-cgi/l/email-protection#d1b3b3b0b8bdb4a891bcb0b8bdffbfb8b9ffb6bea7"><span class="__cf_email__" data-cfemail="fe9c9c9f97929b87be939f9792d0909796d0999188">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal
Antibodies for Assay Creation
Description of Technology
Crimean-Congo hemorrhagic fever (CCHF) is the most widespread form
of viral hemorrhagic fever, found in Eastern and Southern Europe, the
Mediterranean, northwestern China, central Asia, Africa, the Middle
East, and the Indian subcontinent. Typically beginning with non-
specific fever, myalgia, nausea, diarrhea, and general malaise,
symptoms of infection with the tick-borne CCHF virus (CCHFV) can
rapidly progress to hemorrhagic manifestations, with case fatality
rates as high as 30-40% in some regions. Critically, there are no
approved vaccines for CCHF, and prevention is limited to control of
exposure to infected ticks and livestock.
Researchers at the Vaccine Research Center (VRC) of the National
Institute of Allergy and Infectious Disease (NIAID) have recently
demonstrated robust immunogenicity and significant protection in a
Rhesus macaque model of CCHF following vaccination with a novel repRNA
vaccine. Single memory B cells from peripheral blood mononuclear cells
(PBMCs) were isolated from the vaccinated macaques to derive monoclonal
antibodies that target the nucleocapsid protein (NP) of CCHFV, which
plays a critical role in the replication and pathogenesis of the virus.
This technology comprises mAbs with strong potential for the
development of diagnostic tools, in vitro assays, research reagents,
and other analytical methods for CCHFV NP recognition.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications:
<bullet> Development of diagnostic assays for rapid, accurate CCHFV
detection in clinical and non-clinical settings.
Competitive Advantages:
<bullet> There are no readily available antibodies that bind to the
NP protein of CCHFV.
Development Stage: Preclinical.
Relevant Publications: Hawman DW, et al. A replicating RNA vaccine
confers protection in a rhesus macaque model of Crimean-Congo
hemorrhagic fever. NPJ Vaccines 2024;9:86. <a href="https://doi.org/10.1038/s41541-024-00887-z">https://doi.org/10.1038/s41541-024-00887-z</a>.
Inventors: Daniel Douek, David Hawman, Leonid Serebryannyy, Noemia
Santana Lima, Chaim Schramm, Sarah Smith (Kerscher), Amy Henry, Alicen
Spaulding (all of NIAID)
Intellectual Property: HHS Reference No. E-129-2025.
Licensing Contact: To license this technology, please contact Brian
Bailey at 240-669-5128, or <a href="/cdn-cgi/l/email-protection#cba9a9aaa2a7aeb28ba6aaa2a7e5a5a2a3e5aca4bd"><span class="__cf_email__" data-cfemail="3e5c5c5f57525b477e535f57521050575610595148">[email protected]</span></a>, and reference E-129-
2025.
Dated: June 30, 2025.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2025-12455 Filed 7-2-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 3, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.